Hwang, William L. http://orcid.org/0000-0003-4514-8837
Jagadeesh, Karthik A.
Guo, Jimmy A.
Hoffman, Hannah I.
Yadollahpour, Payman http://orcid.org/0000-0003-1984-5014
Reeves, Jason W.
Mohan, Rahul
Drokhlyansky, Eugene
Van Wittenberghe, Nicholas
Ashenberg, Orr
Farhi, Samouil L. http://orcid.org/0000-0003-1359-4568
Schapiro, Denis http://orcid.org/0000-0002-9391-5722
Divakar, Prajan
Miller, Eric http://orcid.org/0000-0002-3243-4968
Zollinger, Daniel R.
Eng, George
Schenkel, Jason M.
Su, Jennifer
Shiau, Carina
Yu, Patrick
Freed-Pastor, William A. http://orcid.org/0000-0002-7377-2111
Abbondanza, Domenic http://orcid.org/0000-0002-7202-0225
Mehta, Arnav
Gould, Joshua http://orcid.org/0000-0001-9581-5461
Lambden, Conner
Porter, Caroline B. M.
Tsankov, Alexander
Dionne, Danielle
Waldman, Julia
Cuoco, Michael S. http://orcid.org/0000-0003-2163-5120
Nguyen, Lan
Delorey, Toni http://orcid.org/0000-0001-6614-3803
Phillips, Devan
Barth, Jaimie L.
Kem, Marina
Rodrigues, Clifton
Ciprani, Debora
Roldan, Jorge http://orcid.org/0000-0002-4825-008X
Zelga, Piotr http://orcid.org/0000-0003-1311-7980
Jorgji, Vjola
Chen, Jonathan H.
Ely, Zackery
Zhao, Daniel
Fuhrman, Kit
Fropf, Robin
Beechem, Joseph M.
Loeffler, Jay S.
Ryan, David P.
Weekes, Colin D.
Ferrone, Cristina R.
Qadan, Motaz
Aryee, Martin J. http://orcid.org/0000-0002-6848-1344
Jain, Rakesh K. http://orcid.org/0000-0001-7571-3548
Neuberg, Donna S. http://orcid.org/0000-0003-2566-3145
Wo, Jennifer Y.
Hong, Theodore S.
Xavier, Ramnik
Aguirre, Andrew J.
Rozenblatt-Rosen, Orit http://orcid.org/0000-0001-6313-3570
Mino-Kenudson, Mari http://orcid.org/0000-0002-9092-2265
Castillo, Carlos Fernandez-del
Liss, Andrew S. http://orcid.org/0000-0002-4040-9172
Ting, David T. http://orcid.org/0000-0002-3261-2322
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Regev, Aviv http://orcid.org/0000-0003-3293-3158
Funding for this research was provided by:
Ludwig Institute for Cancer Research
Lustgarten Foundation
Article History
Received: 28 August 2021
Accepted: 16 June 2022
First Online: 28 July 2022
Competing interests
: A.R. is a cofounder and equity holder of Celsius Therapeutics, an equity holder in Immunitas, and was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics and Asimov. From 1 August 2020, A.R. is an employee of Genentech. T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is also a cofounder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics. He is President of Break Through Cancer. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript. T.J.’s laboratory also currently receives funding from Johnson & Johnson Lung Cancer Initiative, but this funding did not support the research described in this manuscript. D.T.T. has received consulting fees from NanoString Technologies, which was used in this work. D.T.T. has received consulting fees from ROME Therapeutics, Foundation Medicine, EMD Millipore Sigma and Pfizer that are not related to this work. D.T.T. is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, which is not related to this work. D.T.T. receives research support from ACD-Biotechne, PureTech Health and Ribon Therapeutics, which was not used in this work. M.M.-K. has served as a compensated consultant for H3 Biomedicine and AstraZeneca and received a research grant (to institution) from Novartis that is not related to this work. R.K.J. received consultant fees from Elpis, Pfizer, SPARC and SynDevRx; owns equity in Accurius, Enlight and SynDevRx; serves on the Board of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors and Tekla World Healthcare Fund; and received a Research Grant from Boehringer Ingelheim (all not related to this work). The interests of D.T.T., M.M.-K. and R.K.J. were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict of interest policies. O.R.R. is a co-inventor on patent applications filed by the Broad Institute for inventions related to single-cell genomics. O.R.R. is an employee of Genentech since 19 October 2020. W.L.H., K.A.J., J.A.G., H.I.H., T.J. and A.R. are co-inventors on U.S. Provisional Patent Application no. 63/313,596 (related to this work). All other authors declare no competing interests.